Cargando…

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Detalles Bibliográficos
Autores principales:	Gantenbein, Andreas R., Agosti, Reto, Kamm, Christian P., Landmann, Gunther, Meier, Niklaus, Merki-Feld, Gabriele Susanne, Petersen, Jens A., Pohl, Heiko, Ryvlin, Philippe, Schankin, Christoph J., Viceic, Dragana, Zecca, Chiara, Schäfer, Elisabeth, Meyer, Ina, Arzt, Michael E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764682/ https://www.ncbi.nlm.nih.gov/pubmed/36536271 http://dx.doi.org/10.1186/s10194-022-01530-9

Ejemplares similares

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
por: Gantenbein, Andreas R., et al.
Publicado: (2022)

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
por: Gantenbein, Andreas R, et al.
Publicado: (2021)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study
por: Agosti, Reto, et al.
Publicado: (2023)

Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study
por: Merki-Feld, Gabriele S., et al.
Publicado: (2021)

Migraine and Happiness
por: Pohl, Heiko, et al.
Publicado: (2022)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
por: Merki-Feld, Gabriele S, et al.
Publicado: (2015)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Nosology and treatment of primary headache in a Swiss headache clinic
por: Kozak*, S., et al.
Publicado: (2005)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users
por: Merki-Feld, Gabriele S., et al.
Publicado: (2017)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Dealing with Headache: Sex Differences in the Burden of Migraine- and Tension-Type Headache
por: Neumeier, Maria Susanne, et al.
Publicado: (2021)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
por: Silvestro, Marcello, et al.
Publicado: (2021)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Self-reported headache among the employees of a Swiss university hospital: prevalence, disability, current treatment, and economic impact
por: Sokolovic, Emina, et al.
Publicado: (2013)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials
por: Di Tanna, Gian Luca, et al.
Publicado: (2019)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021)

Impact of COVID-19 on chronic migraine treated with erenumab: a case report
por: Grassini, Alberto, et al.
Publicado: (2021)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

Interim report on existing beam instrumentation at the Swiss Light Source storage ring
por: Streun, A., et al.
Publicado: (2011)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b9qr0l5o9s6rmq3j3sp2pjmppk